Teva Branded Pharmaceutical Products R&D, Inc. et al v. Amneal Pharmaceuticals of New York, LLC et al

Why this Matters:

The plaintiffs argue that defendants improperly listed certain patents in the Orange Book to maintain exclusivity and block other generics from entering the market in violation of federal patent and antitrust law. Patent abuses can distort the market for prescription drugs and drive up prices for consumers.

Potential Impact:

Improper patent listings in the Orange Book can undermine fair competition and prohibit or delay consumers from accessing lower-cost generic drugs.